Travere Therapeutics
TVTX
174 hedge funds and large institutions have $1.9B invested in Travere Therapeutics in 2023 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 84 increasing their positions, 29 reducing their positions, and 17 closing their positions.
190% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 29
118% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 17
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
24% more capital invested
Capital invested by funds: $1.53B → $1.9B (+$367M)
13% more funds holding
Funds holding: 154 → 174 (+20)
2.55% more ownership
Funds ownership: 113.53% → 116.08% (+2.6%)
25% less call options, than puts
Call options by funds: $4.63M | Put options by funds: $6.17M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$37.3M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$33.3M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$32.2M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$28.5M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$24.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$83.8M |
| 2 |
Goldman Sachs
New York
|
-$39.3M |
| 3 |
B
Braidwell
Stamford,
Connecticut
|
-$30.6M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$25.8M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$13.2M |
TVTX Hedge Fund Activity: Q1 2023 in Review
174 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q1 2023, worth a combined $1.9B — up 24% from $1.53B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new TVTX positions and 17 closed out — a net gain of 20 holders — while 84 added to existing stakes and 29 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $37.3M. The largest seller was RA Capital Management, exiting entirely with an estimated $83.8M sold.
- 174 institutional investors held Travere Therapeutics (TVTX) as of Q1 2023, up from 154 in Q4 2022.
- Funds reported $1.9B of Travere Therapeutics stock for Q1 2023, up 24% quarter-over-quarter.
- 37 funds opened new Travere Therapeutics positions in Q1 2023 and 17 closed out, a net change of +20 holders.
- The largest Travere Therapeutics buyer in Q1 2023 was Janus Henderson Group, an estimated $37.3M added.
- The largest Travere Therapeutics seller in Q1 2023 was RA Capital Management, an estimated $83.8M sold.
Based on aggregated 13F filings for Q1 2023.